BMS-103
BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 1675202-86-4
- Formula: C25H29NO4
- Molecular Weight:407.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
5.7 μM
Compound: A1
|
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37226718] |
Chemical Information
-
CAS No. 1675202-86-4
-
Molecular Weight 407.50
-
Formula C25H29NO4
-
SMILES
CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)